Ipsen SA’s specialty care business expects headwinds in 2021 from a phased launch of a generic version of its somatostatin analog Somatuline (lanreotide) in Europe and a limited impact from a potential launch of octreotide (another somatostatin analog) or lanreotide generics in the US.
Nonetheless, the mid-sized Paris-headquartered pharmaceutical company is expecting group sales to increase by more than 4% in 2021 at constant...








